Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
CAMBRIDGE, Mass., May 10, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Bank of America Merrill Lynch 2017 Health Care Conference
Wednesday, May 16, 2017 at 12:20 p.m. ET in Las Vegas, NV
UBS Global Healthcare Conference
Tuesday, May 23, 2017 at 9:00 a.m. ET in New York, NY
A webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after each event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
